Methylene blue vs NAD⁺ precursors
Two approaches to mitochondrial energy with very different risk profiles: an approved drug repackaged as a biohack, versus a supplement that reliably moves a biomarker and nothing more.
Short answer
The clearest difference is regulatory. Methylene blue is FDA-approved, and NAD⁺ precursors are not FDA-approved. Methylene blue suits a reader who puts weight on FDA approval, while NAD⁺ precursors are marketed for cellular energy and anti-aging. On the evidence, both have human clinical data.
Methylene blue
An FDA-approved drug (for methemoglobinemia) with a single-dose human memory/fMRI signal and a plausible low-dose mitochondrial mechanism — but longevity claims are preclinical and it risks serotonin syndrome with antidepressants.
Full Methylene blue evidence reviewNAD⁺ precursors
NR / NMN
Oral NR/NMN reliably raise blood NAD⁺ in RCTs — but whether that translates into anti-aging outcomes is still open.
Full NAD⁺ precursors evidence reviewMethylene blue vs NAD⁺ precursors: head to head
- FDA status / approved use
Methylene blue
FDA-approved drug for methemoglobinemia; also sold as a wellness supplement in unregulated formsNAD⁺ precursors
Marketed as longevity supplements- Marketed for
Methylene blue
Mitochondrial energy, nootropic, anti-agingNAD⁺ precursors
Cellular energy, anti-aging- Outcome areas
Methylene blue
Mitochondrial / cellular energy; Cognitive function / memory; Longevity / lifespanNAD⁺ precursors
Mitochondrial / cellular energy; Longevity / lifespan- Evidence grade
Methylene blue
Clinical dataNAD⁺ precursors
Clinical data- How it works
Methylene blue
Alternative mitochondrial electron carrier at low doses; pro-oxidant at high dosesNAD⁺ precursors
Precursors absorbed and converted into NAD+, a molecule that declines with age- Route and dosing
Methylene blue
Oral liquid, sold in dropper bottlesNAD⁺ precursors
Oral supplement- Headline human result
Methylene blue
7% increase in correct memory responses after a single low oral dose in 26 healthy adults (randomized, placebo-controlled)NAD⁺ precursors
Raise blood NAD+ in human trials, but no human trial shows they extend healthspan, prevent disease or slow aging- Strongest evidence
Methylene blue
fMRI RCT, Radiology 2016Methylene blue evidence reviewPubMed 27351678NAD⁺ precursors
NR PK RCT, Nat Commun 2016NAD⁺ precursors evidence reviewPubMed 27721479- Key safety signal
Methylene blue
Potent MAO inhibitor; can cause fatal serotonin syndrome with SSRIs, SNRIs or other serotonergic drugsNAD⁺ precursors
Well tolerated in short-term trials; no long-term safety data- How it is obtained
Methylene blue
Prescription drugNAD⁺ precursors
Over the counter as a dietary supplement
| Methylene blue | NAD⁺ precursors | |
|---|---|---|
| FDA status / approved use | FDA-approved drug for methemoglobinemia; also sold as a wellness supplement in unregulated forms | Marketed as longevity supplements |
| Marketed for | Mitochondrial energy, nootropic, anti-aging | Cellular energy, anti-aging |
| Outcome areas | Mitochondrial / cellular energy; Cognitive function / memory; Longevity / lifespan | Mitochondrial / cellular energy; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Alternative mitochondrial electron carrier at low doses; pro-oxidant at high doses | Precursors absorbed and converted into NAD+, a molecule that declines with age |
| Route and dosing | Oral liquid, sold in dropper bottles | Oral supplement |
| Headline human result | 7% increase in correct memory responses after a single low oral dose in 26 healthy adults (randomized, placebo-controlled) | Raise blood NAD+ in human trials, but no human trial shows they extend healthspan, prevent disease or slow aging |
| Strongest evidence | fMRI RCT, Radiology 2016Methylene blue evidence reviewPubMed 27351678 | NR PK RCT, Nat Commun 2016NAD⁺ precursors evidence reviewPubMed 27721479 |
| Key safety signal | Potent MAO inhibitor; can cause fatal serotonin syndrome with SSRIs, SNRIs or other serotonergic drugs | Well tolerated in short-term trials; no long-term safety data |
| How it is obtained | Prescription drug | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Methylene blue is a genuine drug, FDA-approved for methemoglobinemia rather than aging, with a plausible low-dose electron-carrier mechanism and one randomized single-dose brain-imaging study linking it to improved memory retrieval; its anti-aging claims are preclinical only. It also has a hormetic dose-response where high doses flip to pro-oxidant, and as a potent MAO-A inhibitor it can trigger potentially fatal serotonin syndrome with SSRIs, SNRIs or other serotonergic drugs, a documented interaction rather than a theoretical one. NAD+ precursors carry none of that: they raise blood NAD+ in randomized trials, look safe short-term, and likewise show no healthspan benefit. The two have not been compared directly.
Methylene blue fits if
Nobody should approach this as a supplement; if it is considered at all it belongs in a conversation with a clinician, and it is simply off the table for anyone on a serotonergic antidepressant.
NAD⁺ precursors fits if
Someone who wants the mitochondrial-energy idea without a drug's interaction profile, accepting that raising NAD+ is exactly where the evidence stops.
Methylene blue vs NAD⁺ precursors: common questions
- Is methylene blue FDA-approved but NAD⁺ precursors not?
- Yes. Methylene blue is an FDA-approved drug for methemoglobinemia; also sold as a wellness supplement in unregulated forms. NAD⁺ precursors are marketed as longevity supplements.
- Which has stronger human evidence, methylene blue or NAD⁺ precursors?
- Neither clearly. Both have human clinical data. The key source for methylene blue is fMRI RCT, Radiology 2016; for NAD⁺ precursors, it is NR PK RCT, Nat Commun 2016.
- What are the main safety concerns with methylene blue and NAD⁺ precursors?
- Methylene blue is a potent MAO inhibitor; can cause fatal serotonin syndrome with SSRIs, SNRIs or other serotonergic drugs. NAD⁺ precursors are well tolerated in short-term trials; no long-term safety data.
Key studies behind each
Methylene blue
- Rodriguez P, Zhou W, Barrett DW, et al. (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. PubMed 27351678
- Ramsay RR, Dunford C, Gillman PK. (2007). Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. PubMed 17721552
- Zuschlag ZD, Warren MW, K Schultz S. (2018). Serotonin Toxicity and Urinary Analgesics: A Case Report and Systematic Literature Review of Methylene Blue-Induced Serotonin Syndrome. Psychosomatics. PubMed 30104021
NAD⁺ precursors
- Trammell SA, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. PubMed 27721479
- Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. PubMed 29599478
- Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. PubMed 33888596
- Liao B, Zhao Y, Wang D, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. PubMed 34238308
The full evidence reviews
- Methylene blue: the longevity 'biohack' that's actually a drug
Low-dose methylene blue has a plausible mitochondrial mechanism and a real single-dose memory signal — but it's an FDA-approved drug, not a supplement, its anti-aging claims are preclinical, and it can cause fatal serotonin syndrome with antidepressants.
Updated August 2026
- NAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term, but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
Updated October 2026
Where to get it
Where to get NAD⁺ therapy
Telehealth services offering NAD⁺ as oral precursors, prescription injections, or clinic IV drips. Formats and pricing vary — confirm current NAD⁺ (NR & NMN) options with the provider.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost telehealth NAD⁺ within a broader longevity stack
- HealthRXPartner
NAD⁺ alongside sermorelin and GLP-1 care from one telehealth pharmacy
Bodybuilding Health+PartnerNAD⁺ from Bodybuilding.com's telehealth program
Provider reviews we publish: System LabsCoreAge RxEmbody NAD+DudeMedsCareBareRX10rx